Patients receiving standard chemotherapy regimens for solid tumors are at lower risk for development of febrile neutropenia and infection than patients who undergo bone marrow or stem cell transplantation. Interventions in these two different groups of patients for the prevention of infection can be expected to differ substantially in terms of level of effectiveness. PEP resources and evidence categorization is grouped for general patients with cancer and patients undergoing high-dose chemotherapy and bone marrow or any type of stem cell transplantation separately. This general section is applicable to any patients that are not undergoing transplantation.
This topic was updated on Septermber 22, 2016.